HR 3379
116th Congress
House
Health
Drug safety, medical device, and laboratory regulation
Licensing and registrations
Marketing and advertising
PRICED Act
Introduced: June 20, 2019
Introduced by:
Schakowsky, Janice D.
Democratic
· Illinois
See on congress.gov
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 21, 2019
Referred to the Subcommittee on Health.
Jun 20, 2019
Referred to the House Committee on Energy and Commerce.
Jun 20, 2019
Introduced in House
Plain-English summary
Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act
This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period.
This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
2